I-Mab Announces Closing of the Divestiture of Business Operations in China
- Written by PR Newswire
ROCKVILLE, Md., April 3, 2024 /PRNewswire/ -- I-Mab (the "Company") (NASDAQ: IMAB) a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced that all conditions precedent to the divestiture transaction...
Read more: I-Mab Announces Closing of the Divestiture of Business Operations in China